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Abstract
Background: The association of the human herpesvirus-8/Kaposi's sarcoma (KS)-associated herpesvirus
(HHV-8/KSHV) serology with various malignancies in Tanzania is not currently well established while
previous studies were based on either PCR or immunofluorescence assays [IFA] but not with a sensitive
enzyme-linked immunosorbent assay (ELISA). Selected archival diagnostic biopsies (n = 184) and sera from
indigenous patients with KS (n = 120), non-KS tumors (n = 24) and non-neoplastic lesions (n = 40) at
Muhimbili National Hospital (MNH), Tanzania, were evaluated by diagnostic histopathology,
immunohistology [anti-HHV-8 latency-associated nuclear antigen (LANA)] and serology for HIV (ELISA)
and HHV-8 (IFA and ELISA).
Results: About 66.3% (n = 122) cases including AIDS-associated Kaposi's sarcoma (AKS) (n = 93), reactive
conditions (n = 28) and only one non-KS tumour were HIV positive. Endemic KS (EKS) patients were
mostly males (96.3%, 26/27) who were less (69.9%, 65/93) predominant in AIDS-associated (AKS). A high
(89%) percentage of patients with anti-HHV-8 antibodies was found in the cohort including the HIV
positive (92%) cases, males (81.2%), KS patients (93%), non-KS tumors (92%), and reactive conditions
(75%). All HHV-8 seronegative KS cases were nodular stage whereas both sera and corresponding biopsies
from early stage KS were HHV-8+. Assay sensitivity, positive predictive value (PPV) and specificity were
98.6%, 93.5% and 16.7% for IFA and 93.5%, 98.6% and 50.0% for ELISA respectively.
Conclusion: HHV-8 seroprevalence at MNH appears high as expected among AKS cases and males but
also in non-KS patients. ELISA showed a combination of high HHV-8 sensitivity as well as higher PPV and
specificity than IFA which however, showed higher sensitivity. The apparent stage-dependent, inverted
serum HHV-8 immunoreactivity supports a notion of viral immune-segregation during KS development.
Routine HHV-8 screening should be considered particularly in patients at risk of KS and for selection of
blood/organ donations.
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Background
The HIV and AIDS epidemic has dramatically increased
the frequency of different malignancies particularly
Kaposi's sarcoma (KS) and certain malignant lymphoma
(ML) which are associated with the novel human herpes-
virus type 8 (HHV-8)/Kaposi's sarcoma-associated herpes
virus (KSHV) and have become a major health concern in
sub-Saharan Africa including Tanzania [1-3]. The preva-
lence of HHV-8 varies from high-endemicity (30–70%)
areas (sub-Saharan Africa), intermediate (5–20%) [Medi-
terranean] and low (≤ 5%) (Northern Europe, USA,
south-east Asia and Japan) reflecting the KS and HIV epi-
demiology [4,5]. HHV-8 has a high (≈50%) prevalence in
the healthy Tanzanian population (blood donors)
although the prevalence in Tanzanian patients with and
without tumors is poorly documented [6]. Seroconver-
sion to HHV-8 precedes and therefore is predictive of KS
development [4] and serodetection may also help to con-
firm KS diagnosis in suspect and/or borderline tumour
lesions. HHV-8 transmission is known to occur both hor-
izontally (orally, sexually and parenterally) and vertically
(mother-to-child) particularly in endemic areas [7,8].
Obviously, large-scale HHV-8 screening would be benefi-
cial and allow preventive/therapeutic interventions
including possible anti-HHV-8 vaccination in at-risk pop-
ulations, but this is not yet well documented in Africa,
particularly Tanzania. Previous studies on HHV-8 in Tan-
zania were based on polymerase chain reaction (PCR)
assay which is not readily and widely available in
resource-constrained developing countries [5,6,9]. Fur-
thermore, the tested non-KS Tanzanian sera in the previ-
ous study by Massambu et al., (2003) [6] were very few
calling for the current larger study of hospital patients (KS,
non-KS neoplasia and non-malignant clinical condi-
tions), for comparison with our previous reports includ-
ing that on healthy blood donors, which was based on
immunofluorescence assay (IFA) and real-time PCR [5],
The use of IFA necessitates culturing and subsequent
processing of a HHV-8+ body cavity-based lymphoma
(BCBL-1) cell line or another B-cell line (BCP-1) which
may not be readily available and affordable in Tanzania
particularly on a routine/large scale screening basis.
Enzyme-linked immunoassays (ELISA) do not involve the
use of cell cultures and thus provide an easy and more
affordable screening method for HHV-8 infection. HHV-8
sero-detection technology is still a developing area and
new assays like ELISAs may not yet have been tested in the
high-endemicity African sera as compared to IFA [4,10].
Our present study therefore, compares IFA and ELISA for
HHV-8 serology of indigenous Tanzanians thus establish-
ing an assay for possible routine use. Furthermore,
although it is known that HIV transactivates HHV-8/
KSHV infection mostly by its Tat protein, the association
of HHV-8 and HIV with non-KS neoplasia and non-malig-
nant (reactive) conditions in Tanzania has not yet been
examined and is therefore evaluated in the present study
[6].
Results
Demography
A total of 184 selected biopsies and corresponding sera
available at MNH/MUHAS between 1990 and 2001 from
indigenous African patients were included in the study. Of
these patients, 120(65%) had KS, 24(13%) non-KS
tumors and 40(22%) non-malignant (reactive) condi-
tions. The male:female ratio was 2.75:1 for KS, 3:1 for
non-KS tumors and almost 1:1 for reactive, non-malig-
nant conditions [Figure 1(a)] and (Table 1). The mean age
for males was 36.6 years ranging from 12–70 and for
females 32.7 years ranging from 17–50 [Table 1].
Histopathology
Of the KS cases, most (68.7%, 82/120) were nodular stage
[Figure 1(b)] with cutaneous (87.8%, 72/82) or lymphad-
enopathic (12.2%, 10/82) localization [Table 2(a)]. The
non-KS tumors included malignant lymphomas (45.8%),
epithelial cancers (25.0%), soft tissue tumors (25.0%)
and one neuroendocrine tumor (4.2%) [Table 2(b)]. Most
of non-neoplastic biopsies came from patients with reac-
tive lymphadenitis and other inflammatory conditions.
HIV serology
Most (66.3%, 122/184) studied sera were HIV positive
(Table 1). Females were only 3.7% (1/27) among EKS
patients and 30.1% (28/93) in AKS whereas males were
predominant in both KS types which differences were sta-
tistically significant (χ2 = 7.96, p = 0.0048) [Table 1].
Most KS cases 77.5%, (93/120) were HIV+ (AKS) and
22.5% (27/120) HIV- (EKS) [χ2 = 28.02, p < 0.001]. How-
ever, most sera from patients with reactive conditions
(70.0%, 28/40) were also HIV+ but most (95.8%, 23/24)
non-KS tumor patients were HIV negative. The difference
between HIV infection amongst KS and non-KS tumor
patients was statistically significant (two-tailed p-value =
0.046) [Table 1].
HHV-8 serology
The HHV-8 serology results are summarized in table 3 and
4. Most (89.0%, 164/184) screened cohort sera were
HHV-8 seropositive based on either IFA (Figure 2) or
ELISA indicating a high prevalence among this cohort of
MNH patients [Table 3 and 4]. HHV-8 seroprevalence was
highest (93.3%, n = 112/120) for KS cases, followed by
non-KS tumors (91.7%, n = 22/24) and lowest (75.0%, n
= 30/40) in non-malignant conditions. This difference in
HHV-8 seroprevalence between the three disease groups
was statistically highly significant (χ2 = 8.35, p = 0.0039)
[Table 3].Infectious Agents and Cancer 2008, 3:10 http://www.infectagentscancer.com/content/3/1/10
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Sex data was available for 154 HHV-8 seropositive cases
and most (81.2%, 125/154) of them were males and only
18.8% (29/154) females. Male HHV-8 seroprevalence was
particularly high (90.2%, 92/102) among KS patients and
less among non-KS tumors (77.3%, 17/22) and non-neo-
plastic conditions (53.3%, 16/30) which difference
appeared statistically highly significant (χ2 = 20.86, p =
0.00003) [Figure 3].
Of all HHV-8 serology tests, 79 specimens were assayed by
both IFA and ELISA and 92.4% (73/79) showed concord-
ance and most (91.1%, 72/79) were ELISA+/IFA+ as well
as one case (1.3%, 1/79) double negative [Figure 4]. How-
ever, 7.6% (6/79) the specimens were ELISA/IFA discord-
ant including those ELISA-/IFA+ (6.3%, 5/79), and one
ELISA+/IFA- case (1.3%, 1/79) [Figure 4]. Thus, although
IFA appeared to have a higher (98.6%) assay sensitivity
[confidence interval (CI) = 91.6–99.9%], it also showed
lower specificity (16.7%, CI = 0.9–63.5) and positive pre-
dictive value (PPV) [93.5%, CI = 84.8–97.6], compared to
ELISA which showed a reasonably high (93.5%, CI =
84.8–97.6) sensitivity, as well as higher PPV (98.6%, CI =
91.6–99.9) and specificity (50.0%, CI = 2.7–97.3). How-
ever, it appears [Figure 2(a–d)] that IFA can clearly visual-
ize latent [latency-associated nuclear antigen (LANA)]
[Figure (2a &2d)] as well as lytic [Figure 2b &2c] antibody
reactivity allowing quantification of both latent and lytic
HHV-8 infection within one individual [Figure 2(d)].
HIV and HHV-8 correlations
Evidently, most (70.3%, 114/162) HHV-8 seropositive
patients appeared also, co-infected with HIV and con-
versely, most (80.0%, 12/20) of those HHV-8 seronega-
tive were also non-reactive for anti-HIV antibodies which
difference appeared statistically highly significant (P =
0.003 Fisher Exact Test) [Table 4].
Immunohistochemistry (IHC)
All early stage KS including patch (17.5%, 21/120) and
plaque (14.2%, 17/120) were cutaneous and HHV-8
LANA+ (Figure 5) whereas two apparently HHV-8 seron-
egative KS were nodular stage. Similarly, although all the
HHV-8 positive KS sera came from patients with LANA+
biopsies (Figure 5), about 6.7% (8/120) of corresponding
Cutaneous nodular AKS: gross picture of the right leg of an African patient showing multiple nodules and macular (patch/ plaque) lesions [a] and a micrograph showing predominance of spindle cells (SC) in a H & E section [b] × 400 Figure 1
Cutaneous nodular AKS: gross picture of the right leg of an African patient showing multiple nodules and mac-
ular (patch/plaque) lesions [a] and a micrograph showing predominance of spindle cells (SC) in a H & E section 
[b] × 400.Infectious Agents and Cancer 2008, 3:10 http://www.infectagentscancer.com/content/3/1/10
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KS sera were HHV-8 negative indicating a tissue-serum
discrepancy.
Discussion
All the three studied Tanzanian disease groups showed
comparable demographical features and the male pre-
dominance in all KS types is concordant with previous
findings by us and others [5,6,8]. The relatively high sero-
prevalence for HHV-8/KSHV in patients with non-KS
tumors and non-neoplastic (reactive) conditions has not
been previously documented in Tanzania and is compati-
ble with a relatively high endemic incidence of HHV-8
infection [5,6].
The rather high prevalence of HIV infection in two-thirds
of the studied cohort patients at MNH is alarming but also
reflects a KS diagnostic selection bias. The dramatic (8-
fold) difference in the male:female ratio of EKS (1:27) and
AKS (1:3) confirms previous reports from Tanzania, east-
ern Africa and elsewhere [8,11-15]. This sex ratio decline
in AKS apparently, reflects an increased frequency of HIV
infected sexually active females, compared to males of the
same age group and a suggested biological gender resist-
ance for females to non-HIV forms of KS [EKS, classic
(CKS) and iatrogenic (IKS)] which clearly show a male
predominance particularly in homosexuals
[2,8,11,14,16,17]. The finding that most non-KS tumors
in our selected cohort were HIV negative emphasizes the
notion that essentially, KS today is an AIDS-defining
malignancy.
As expected by their KS diagnosis, the HHV-8 seropreva-
lence (90%) in the studied cohort sera was higher than
that in the healthy non-hospitalized population of about
50% in Tanzania [5,6] and of 70% in sub-Saharan Africa
[4]. The slightly lower seroprevalence observed in our pre-
vious PCR study could be attributed to the small KS sam-
ple size compared to that in our present study [6] but
differences in assay sensitivity/specificity should also be
considered [4]. Obviously, this high HHV-8 frequency in
patients at MNH implies a potential high risk of
Table 1: Demographic characteristics of studied MNH patients with KS, non-KS tumors and reactive lesions in association with HIV 
serostatus
Histological 
diagnosis
Age 
characteristics 
(years)
Age-group (years) Sex HIV serostatus Overall 
cohort(Years)
Adults (≥15) Children (<15) Male Female Positive Negative
Kaposi's 
sarcoma (KS) 
[120 cases]
Mean age 35.8 na* 36.6 32.7 35.5 37.2 35.6
Age-Range 17–70 na* 12–70 17–65 12–70 19–65 12–70
Total (%) 119 (99.2) 1 (0.8) 88 (73.3) 32 (26.7) 93 (77.5) 27 (22.5) 120 (100.0)
Non-KS 
malignancies 
[24 cases]
Mean age 36.5 8.5 31.1 22.4 na * 29.6 29.2
Age-Range 15–63 5–14 5–63 7–27 na * 5–63 5–63
Total (%) 18 (75.0) 6 (25.0) 18 (75.0) 6 (25.0) 1 (4.2) 23 (95.8) 24 (100.0)
Non-malignant 
cases [40 
cases]
Mean age 34.9 8.0 37.5 26.1 31.8 31.2 31.6
Age-Range 18–52 2–11 9–52 2–47 2–52 9–44 2–52
Total (%) 36 (90.0) 4 (10.0) 21 (52.5) 19 (47.59 28 (70.0) 12 (30.0) 40 (100.0)
Grand total (%) 173 (94.0) 11 (6.0) 127 (69.0) 57 (31.0) 122 (66.3) 62 (33.7) 184 (100.0)
Key: na = not applicable, * = only one case available.
Table 2: Histological diagnosis of (a) KS patients and (b) non-KS 
malignancies
(a) KS cases Number Percentage
Lymphadenopathic nodular KS 10 8.7
Nodular KS 72 60
Patch KS 21 17.4
Plaque KS 17 13.9
Total 120 100
(b) Non-KS malignancies Number Percentage
Lymphomas 11 45.8
Epithelial tumors 6 25
Neuroendocrine tumors 1 4.2
Soft tissue tumors 6 25
Total 24 100.0Infectious Agents and Cancer 2008, 3:10 http://www.infectagentscancer.com/content/3/1/10
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parenteral/iatrogenic transmission for both patients and
staff, particularly during blood transfusion and other
invasive procedures, as well as in intravenous (IV) drug
users [4,5,18].
The higher (93%) HHV-8 prevalence among KS cases
compared to non-KS tumors and reactive lesions supports
a causal relationship between the virus and primarily KS
but other lymphoid tumors as primary effusion lym-
phoma (PEL) or body cavity-based lymphoma (BCBL)
and multicentric Castleman's disease (MCD) which may
also be associated with HHV-8 [2,5,19] were surprisingly
not evident in our study.
Evidently, the finding that HHV-8 was more prevalent in
males in all disease groups is concordant to our previous
reports and others [5,6,8,11,20] on HHV-8 seropreva-
lence in KS and that KS is predominantly a male disease in
cutaneous AIDS-associated (AKS), African endemic (EKS),
classical (CKS) and iatrogenic [IKS]/post-transplantation
Kaposi's sarcoma [6,8,11,20] although, we have recently
reported an increased frequency of females with oral AKS
(OAKS) [8]. Furthermore, we have shown previously that
HHV-8 is not only more frequent in males, but that they
appear to have higher viral (HHV-8) loads than females in
both sera and tissue lesions by both immuhistochemistry
and real-time PCR [6,8]. Reasons for this sex differences
are yet not fully clarified although various biological and
socio-behavioral factors were suggested [6,8]. Recently in
a comparative genomic hybridization (CGH) and inter-
phase-fluorescence  in-situ  hybridization (interphase
FISH) study, we have reported cytogenetic differences
between male and female KS patients including the loss of
chromosome Y observed in all early and the majority of
late male AKS and EKS representing a clonal genomic
change [21]. Moreover, in early stage disease loss of Y
chromosome was the only recurrent change found [21].
These features are apparently, mainly related to early male
KS pathogenesis and may therefore indicate cytogenetic
reasons for the sex differences in KS [21]. Furthermore, the
higher seroprevalence of the oncogenic HHV-8 among
male KS patients may also relate to the higher frequency
of KS in males [6,8,20,21].
Interestingly, the male predominance for HHV-8 sero-
prevalence in our current study was also seen in non-KS
and non-neoplastic patients suggesting a possible higher
susceptibility/permissiveness of males to KSHV/HHV-8
infection and/or a high viral transmission among male
homosexuals and intravenous (IV) drug users usually,
mostly males [8,18,22,23]. However, the association of
sex with KS development and HHV-8 infection is yet to be
fully elucidated.
Table 3: Summary of HIV and HHV-8 screening among MNH patients by either IFA or ELISA between 1990 and 2001
Assay IFA ELISA
Disease group Serostatus HHV8+ HHV8- HHV8+ HHV8- Total
KS HIV+ 42 (45.2) 3 (3.2) 46 (49.5) 2 (2.2) 93 (77.5)
HIV- 10 (37.0) 2 (7.4) 15 (55.6) 0 27 (22.5)
All cases 52 (43.3) 5 (4.2) 61 (50.8) 2 (1.7) 120 (100.0)
Non-KS tumors HIV+ 1 (100.0) 0 0 0 1 (4.2)
HIV- 8 (34.8) 1 (4.3) 13 (56.5) 1 (4.3) 23 (95.8)
All cases 9 (37.5) 1 (4.2) 13 (54.2) 1 (4.2) 24 (100.0)
Non-neoplastic HIV+ 11 (39.3) 3 (10.7) 14 (50.0) 0 28 (70.0)
HIV- 0 10 (83.3) 2 (16.7) 0 12 (30.0)
All cases 11 (27.5) 13 (32.5) 16 (40.0) 0 40 (100.0)
Total 72 (39.1) 19 (10.3) 90 (49.0) 3 (1.6) 184 (100.0)
Table 4: Association between HIV and combined (IFA and ELISA) HHV-8 sero-reactivity of studied patients at MNH (1990–2001)
HHV8 [no. (%)] Total [no. (%)]
Antibody Serostatus Positive Negative
HIV Positive 114 (70.3) 8 (40.0) 122 (66.3)
Negative 48 (29.7) 14 (80.0) 62 (33.7)
Total 162 (88.0) 22 (12.0) 184 (100.0)Infectious Agents and Cancer 2008, 3:10 http://www.infectagentscancer.com/content/3/1/10
Page 6 of 9
(page number not for citation purposes)
Our finding that HHV-8 antibody seroprevalent patients
at MNH were 3-times more often HIV co-prevalent than
the HHV-8 seronegative cases is consistent with other
reports [4,18,24] indicating corresponding seroepidemi-
ology for these viruses, partly explaining the much
increased risk of KS development among those HIV and
HHV-8 co-infected as compared to those infected with
either or neither of the viruses [2,4,8,18,24]. Furthermore,
the findings support also the notion of HIV and HHV-8
cross-talk, partly achieved through the transactivation of
KSHV by HIV-Tat as reported previously by us and others
[2,6,9,25]. This HIV-HHV8 cross-talk, calls for exploration
for the development and application of possible com-
bined anti-HIV, anti-HHV-8 and anti-KS prevention and
therapeutic strategies among high-risk groups including
HIV-infected and AIDS patients.
The finding that IFA showed greater sensitivity than ELISA
is probably due to that IFA methods shows antibodies to
both lytic and latent antigens and that lytic are reportedly
more sensitive [5]. However, our finding that ELISA had
apparently, higher positive predictive value as well as spe-
cificity and still had a high sensitivity was unexpected and
particularly favourable as it makes HHV-8 screening more
affordable in a resource-constrained country like Tanza-
nia, mostly lacking the cell culture and fluorescence
microscopy facilities needed in IFA. Consequently, ELISA
can allow larger-scale screening of HIV high-risk groups
IFA microphotographs showing BCBL-1 cytospin cells reactivity to anti-HHV-8 LANA (pink intranuclear dots) [a] and to lytic  (green diffuse cytoplasmic staining) antibodies K8.1 Figure 2
IFA microphotographs showing BCBL-1 cytospin cells reactivity to anti-HHV-8 LANA (pink intranuclear dots) 
[a] and to lytic (green diffuse cytoplasmic staining) antibodies K8.1[b] and ORF 59 [c] 72 hrs after treatment 
with tetra-phobol acetate (TPA) to induce the lytic phase. KS patient's serum was added to BCBL-1 TPA 
treated cytospin cells producing, the lytic green diffuse cytoplasmic staining and latent white intranuclear dots. 
Note that majority of BCBL-1 cells reacted to latent (brown arrow) compared lytic (white arrow) antibodies 
in the index KS patient in [d], all sections × 400.Infectious Agents and Cancer 2008, 3:10 http://www.infectagentscancer.com/content/3/1/10
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including blood/organ donors and thereby prevent KS
development through early antiviral interventions
(including vaccination) [4,5]. However, these findings are
prone to observer errors, sampling bias (hospital data)
including the fact that HHV-8 screening is a field that is
still evolving methodologically [4]. Nevertheless, the IFA
method also appears to afford visual evaluation of the per-
centage seroprevalence of lytic as well as latent anti-HHV-
8 antibodies apparently, allowing categorization of
patients as being in the productive and potentially infec-
tive (lytic) and non-productive but oncogenically more
significant latent phase [2] and may therefore be useful
when such characterization is desired for clinical or public
health interventions.
Our finding that all sera from early stage (patch-plaque)
KS were positive for anti-HHV-8 antibodies while all neg-
ative sera were from LANA+ biopsies of nodular KS
patients, further supports our previous notion of stage-
dependent tissue-serum discrepancy in viral antigen and
antibody expression probably due to virus tissue reten-
tion, immune-segregation and/or selective clearance dur-
ing KS evolution [6,19].
Again, the clear relationship between HHV-8 and HIV
infections and KS prevalence underlines the interaction
between the two viruses being possibly facilitated in part,
by similar transmission patterns and also, their transacti-
vation capacity [2,4,6,19].
Conclusion
HHV-8 seroprevalence in patients at MNH Tanzania
appears to be high as expected, in HIV+ and HIV- KS cases
and males but also in the HIV seronegative non-KS
tumors. ELISA showed a combination of high HHV-8 sen-
sitivity as well as higher PPV and specificity compared to
IFA which however showed higher sensitivity. An appar-
ent stage-dependent tissue-serum discrepancy in HHV-8
antigen and antibody expression seems to support the
notion of immune-segregation and/or selective virus
clearance during the evolution KS. HHV-8 screening of
patients at risk of KS and of blood and organ donors par-
ticularly in high endemic areas will evidently help prevent
development of KS.
Methods
Biopsies
Diagnostic archival biopsies fixed in 10% neutral buffered
formalin and paraffin-embedded (FFPE) and correspond-
ing, available sera and medical records of KS patients
between 1990 and 2001 were retrieved and evaluated
[Dept. Histopathology, Muhimbili National Hospital
(MNH)/Muhimbili University of Health and Allied Sci-
ences (MUHAS), Dar es Salaam] and at the Immunopa-
thology Lab [Karolinska University Hospital Solna,
Stockholm]. Furthermore, available biopsies and corre-
sponding sera from non-KS tumors and reactive condi-
tions from the same period were also evaluated. The
biopsies of reactive conditions included all histologically
non-malignant/inflammatory cases whose sera were
available for analysis. None of the patients had received
any antiretroviral (ARV) or anti-tumour therapy before
the biopsy was taken.
Histology
Routine hematoxylin and eosin (H & E) staining was done
as previously described [8,26] and microscopic evaluation
was done independently by three pathologists as previ-
ously described [8].
Serology
Available sera from patients with histologically diagnosed
KS, non-KS malignancies as well as reactive conditions
were comparatively evaluated for HIV and HHV-8 serol-
ogy. Serology for HIV-1 evaluation (ELISA) was per-
formed at Microbiology/Immunology MUHAS as
previously described [8,27,28].
HHV-8 serology by IFA was performed [Swedish Institute
for Infectious Diseases Control (SMI)] on cytospins of
BCBL-1* cells [29] using patients sera as well as control
lytic (K8.1 and ORF 59) and latent (ORF 73 or LANA)
antibodies [Advanced Biotechnologies Inc. (Columbia,
MD)] as previously described [5,8]. Results were evalu-
ated and documented by microphotography (Immunopa-
thology Lab).
The HHV-8 infected body cavity-based lymphoma (BCBL-
1) cells (kindly provided by G. Gaidano) were derived
from a primary effusion lymphoma (PEL) [30,31], and
cultured [Immune and Gene Therapy Lab., Cancer Center
Karolinska (CCK)] in RPMI 1640 medium (Gibco, BRL,
Total HHV-8 antibody seroprevalence by sex and disease  groups among MNH patients (1990–2001) Figure 3
Total HHV-8 antibody seroprevalence by sex and dis-
ease groups among MNH patients (1990–2001).
Total HHV-8 antibody seroprevalence by sex and disease 
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UK) containing 10% heat-inactivated FCS serum, 2 mM L-
glutamine, 100 IU/ml penicillin and 100 μg/ml strepto-
mycin at 37°C and 5% CO2. To induce lytic gene tran-
scription, cells were cultured with 20 ng/ml of 12-O-
tetradecanoylphorbol-13-acetate (TPA) [Sigma Chemical
Co., St. Louis, Mo.] as previously described, [5,28,32] and
harvested after 72 hours, washed with PBS and fastened
by cytospin on SuperFrost® slides (Menzel GmbH & Co
KG, Braunschweigh, Germany). The slides were fixed for
10 minutes in 4% paraformaldehyde (PFA) and washed
before immunostaining as previously described [5,8].
For HHV-8 antibody evaluation an IgG enzyme immu-
noassay (EIA) Kit (96 Wells, HHV-317-02) Biotrin Inter-
national (Dublin, Ireland) was used. The Biotrin HHV-8
ELISA is a direct EIA based on the binding of HHV-8-spe-
cific antibodies to lytic peptide antigens coupled to micro-
titre test strips. Bound antibodies are detected by an anti-
human IgG peroxidase conjugate and a 3,3',5,5'-tetrame-
thylbenzidine (TMB) dark blue substrate reaction (BioFX
Laboratories, Inc. Owings Mills, MD). The use of lytic pep-
tide epitopes derived from various HHV-8 viral proteins
ensures both a high sensitivity and specificity. The Kit has
no detectable cross-reactivity with HIV/EBV antibodies.
Control sera included those from known HHV-8+ KS
patients while the HHV-8 infected BCBL-1 cells provided
an internal positive control for IFA studies. The negative
controls for both IFA and ELISA included sera from
known HIV and HHV-8 negative non-KS patients and a
buffer (PBS).
Immunohistochemistry (IHC)
Immunostaining with the avidin-biotin complex (ABC)
immunoperoxidase technique was used on KS sections (5
μm) for detection of HHV-8 latency-associated nuclear
antigen (LANA) to compliment histopathology and serol-
ogy, as previously described [8,19,26,33]. Negative con-
trols included sections from non-KS tissues as well as
incubation with PBS instead of the primary antibody. Pos-
itive controls included previously tested KS sections and
FFPE sections of HHV-8 LANA+ cells from a body cavity-
based lymphoma (BCBL-1). The number of LANA+ cells/
HPF (× 400 magnification) was evaluated on micrographs
as previously described [8,19,33].
Microscopy
For microscopy and microphotography an Olympus
BX60, microscope with a digital camera (Sony DKC-5000)
was used as previously described [8,19,33].
Statistical Analysis
The EPI INFO 6 statistical software programme (CDC,
Atlanta, GA) was used. P-values of ≤0.05 were considered
statistically significant. The Fisher exact test was used to
test the significance level where the sample size was small.
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